Innate Pharma announces today a capital increase of a maximum of 24.3 million euros reserved to categories of investors
New data presented at the Annual Meeting of the American Society of Hematology (“ASH”)
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
Innate Pharma SA announces its turnover for the third quarter of 2009 and updates on its cash situation
Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia
Innate Pharma reports Phase II clinical data with IPH 1101 in oncology
Description of the Company’s authorization to purchase of its own shares adopted during the general shareholders’ meeting on june 23, 2009
Innate Pharma enters into a liquidity agreement with Natixis Securities
Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009.
Inserm Transfert and Innate Pharma enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
